FIGHT-207 is a multi-centre international study to evaluate the efficacy and safety of pemigatinib in participants with activating FGFR mutations or translocations.

Full title: Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

This study is currently open at the following centres in the UK:

  • Sarah Cannon Institute, London – Dr Tobias Arkenau
  • University College Hospital, London – Professor John Bridgewater
  • Hammersmith Hospital, London
  • The Christie, Manchester

More details of the study, and European locations currently recruiting, can be found here:

Also, see: and search for Study: FIGHT-207


Back to previous page